Greenway Therapeutix® is Exhibiting at the Generational Dermatology Meeting
Palm Springs, CA, February 14, 2020 – Greenway Therapeutix®, Inc., a Biopharmaceutical company dedicated to the research and development of medical grade cannabinoid therapeutics utilizing nanotechnology, was exhibiting at Generational Dermatology meeting this year in Palm Springs.
Founder and Course Director, Dr. Wendy E. Roberts indicates that Generational Dermatology™ is a multi-decade approach to the evolving aging patient, including Medical, Surgical and Aesthetic Dermatology. This CME meeting is targeted toward the Dermatologist and other CORE specialists of beginning, mid and late career.
The company’s CEO, Dr. Michael Milane, was present for the meeting and the Greenway booth support throughout the conference to address a variety of questions from clinicians in attendance. There was a lot of interest in current clinical findings on Canno Cream™, recent case studies with safety and efficacy data and potential availability for Dermatology offices.
About Greenway Therapeutix
Greenway Therapeutix® is a medically focused Biopharmaceutical company created by doctors and scientists, dedicated to the research and development of medical-grade cannabinoid therapeutic products, while utilizing cutting edge nanotechnology in their skin delivery. High-Potency Cannabidiol (CBD) Therapeutic products are currently in clinical development and testing for the evaluation of multiple inflammatory skin conditions.
Canno Cream™ is the first Dermatology developed and Medical Grade 99% CBD cream with a novel nano CBD formulation, designed to provide potential relief with positive data for a multitude of inflammatory skin conditions. The product is a Cosmeceutical and is only intended for symptom relief and not FDA approved or indicated for any disease conditions.
For more information, visit www.greenwaytherapeutix.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.